Vision Lithium Inc. announced a 15-for-1 share consolidation effective September 28, 2026, reducing its outstanding shares from approximately 293 million to about 19.5 million. The consolidation aims to streamline the company's capital structure without changing its name or stock symbol. Shareholders will have their positions adjusted automatically or via share certificate exchanges through the transfer agent. This move was approved by shareholders earlier in 2026 and is part of Vision Lithium's ongoing efforts to enhance shareholder value as it develops its lithium and base metal projects in Canada.
Vision Lithium's upcoming 15-for-1 share consolidation is announced as context for readers. For those following the Basic Materials sector, here is Pluang's market snapshot as of Sep 24, 2026 17:41 WIB: Of 38 priced US stocks, 9 rose and 25 fell. Notable movers include FCX at USD 71.85 with a 1-day change of -1.01% and a typical hold time of 69 days, WPM at USD 144.09 with a -0.94% change and 99% buy order activity, and DD at USD 129.70 with a -0.93% change and 67% sell order activity.
XRP showed a potential bullish inverse head-and-shoulders pattern with a key resistance neckline near $1.57 and further resistance around $1.60. A decisive and sustained break above these levels is needed to strengthen the bullish case and target $2....
Google announced a new initiative partnering with veterans organizations to help 25,000 veterans, service members, and military spouses enter skilled trades. This effort addresses a nationwide shortage of skilled trade workers driven by increased dem...
OS Therapies announced that the World Health Organization has approved 'Herlystic' as the brand name for its gene-edited cancer immunotherapy OST-HER2. With both the proprietary and nonproprietary names approved, the company is set to begin regulator...
XRP climbed from around $1.27 to test resistance between $1.61 and $1.70 but faced selling pressure that pushed it back to about $1.47. The token is currently testing a critical support zone around $1.42-$1.45, which overlaps with previous resistance...
Ventripoint Diagnostics has successfully completed its annual quality and regulatory audits, including the Medical Device Single Audit Program, ISO 13485:2016, and the EU Medical Device Regulation. These audits confirm the effectiveness of Ventripoin...
